Carnosic Acid (Diterpene)

Carnosic acid is a phenolic diterpene compound found primarily in rosemary that activates antioxidant pathways through Nrf2 signaling. This bioactive compound demonstrates anti-inflammatory properties by inhibiting NF-κB activation and reducing cytokine production.

Origin & History

Carnosic acid is a naturally occurring phenolic diterpene primarily extracted from the leaves of Rosmarinus officinalis (rosemary) and related plants like sage. It is typically isolated through solvent-based extraction methods from rosemary leaves and often standardized in commercial extracts.

Historical & Cultural Context

While isolated carnosic acid lacks documented traditional use, it is a major bioactive component in rosemary extracts, which have been used in Mediterranean folk medicine. Historical applications focused on antioxidant preservation rather than specific medicinal properties of carnosic acid itself.

Health Benefits

• Anti-inflammatory effects: Reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in animal arthritis models (Evidence: Preliminary - animal studies only)
• Bone health support: Ameliorated bone loss and suppressed osteoclastogenesis in diabetic mice with arthritis (Evidence: Preliminary - PMID: 28343998)
• Neuroprotective properties: Pro-drug form improved memory and reduced amyloid plaques in Alzheimer's mice models (Evidence: Preliminary - animal studies)
• Cellular antioxidant protection: Protected retinal cells against oxidative stress-induced death in vitro (Evidence: Preliminary - cell studies)
• Metabolic support: Reduced lipid content and improved gut health in diet-induced obese mice (Evidence: Preliminary - animal studies)

How It Works

Carnosic acid activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, promoting antioxidant enzyme expression including heme oxygenase-1 and glutathione peroxidase. It simultaneously inhibits nuclear factor-κB (NF-κB) translocation, reducing production of inflammatory mediators. The compound also modulates cyclooxygenase-2 (COX-2) and lipoxygenase enzymes involved in inflammatory cascades.

Scientific Research

Current evidence for carnosic acid is limited to preclinical animal and in vitro studies, with no human clinical trials identified. Key studies include arthritis models in diabetic db/db mice showing reduced inflammation and bone loss (PMID: 28343998), and similar anti-inflammatory effects in Wistar rats with collagen-induced arthritis (PMID: 29521424).

Clinical Summary

Current evidence for carnosic acid is limited to preliminary animal studies. Research in arthritic mouse models showed significant reductions in inflammatory cytokines TNF-α, IL-1β, and IL-6 following treatment. One study in diabetic mice with arthritis demonstrated improved bone density markers and reduced osteoclast activity. Human clinical trials are lacking, making therapeutic efficacy in humans unclear.

Nutritional Profile

Carnosic acid is a pure bioactive diterpene compound (phenolic diterpene), not a whole food ingredient, and therefore contains no macronutrients (protein, fat, carbohydrates), fiber, vitamins, or minerals in isolation. Key compositional facts: Carnosic acid (C20H28O4, MW: 332.43 g/mol) constitutes approximately 1.5–2.5% dry weight of rosemary (Rosmarinus officinalis) leaf and up to ~4.6% in concentrated rosemary extracts; it represents roughly 90% of the total antioxidant capacity of rosemary oleoresin. As a bioactive compound, it is a highly lipophilic diterpene phenol containing an ortho-dihydroquinone (catechol) moiety responsible for its radical-scavenging activity. It functions as a pro-drug: upon oxidative activation, it converts to carnosol, rosmanol, and other metabolites. ORAC value of isolated carnosic acid is exceptionally high (~2,500–3,000 µmol TE/g). Bioavailability: absorption is favored by its lipophilic nature (logP ~4.5), enhanced by co-administration with dietary fats; peak plasma concentration reached ~1–2 hours post-ingestion in animal models; undergoes first-pass hepatic metabolism to active metabolites including carnosol; oral bioavailability estimated at 20–40% in rodent models with limited human pharmacokinetic data available. Typical supplemental doses studied range from 30–200 mg/day in preclinical settings.

Preparation & Dosage

No clinically studied human dosages are available. Preclinical studies used 10 μM in cell cultures, 50-100 mg/kg body weight orally in mice, though human equivalent doses have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Carnosol, Rosmarinic acid, Vitamin E, Curcumin, Resveratrol

Safety & Interactions

Safety data for isolated carnosic acid supplements is limited, though rosemary extract containing this compound is generally recognized as safe. No significant adverse effects have been reported in animal studies at typical dosing levels. Potential interactions with anticoagulant medications may occur due to rosemary's blood-thinning properties. Pregnant and breastfeeding women should avoid supplemental doses pending safety research.